Abstract
For more than a decade radioiodinated meta-iodobenzylguanidine (mIBG) has been commonly used for neuroblastoma imaging. The accuracy of this scintigraphic method in detecting both primary and secondary tumour sites is crucial when evaluating the extent of disease. The aim of our study was to assess the impact of high-activity mIBG scintigraphy on neuroblastoma staging. Eighteen scans (TS) were obtained in 15 children after a therapeutic dose of iodine-131 mIBG and compared to diagnostic mIBG scans (DS) (in eight cases with131I-mIBG and in ten cases with123I-mIBG). The superiority of TS over DS was confirmed by the overall results: a total of 220 lesions were disclosed with TS and 171 with DS. However, in only one case did the TS findings, namely skeletal involvement not evidenced on corresponding DS, have an impact on clinical staging. In contrast, neither TS nor DS detected proven bone involvement in four patients. The dose-related sensitivity of mIBG scintigraphy in detecting neuroblastoma tumour sites was confirmed. The ultimate impact of high-dose scans on neuroblastoma management, however, seems limited.
This is a preview of subscription content, log in via an institution to check access.
References
Kinnier-Wilson LM, Draper G.J. Neuroblastoma, its natural history and prognosis: a study of 487 cases.Br Med J 1974; 3: 301–307.
Young JL, Riesl LG, Silverberg E, Horm JW, Miller RW. Cancer incidence, survival, and mortality for children under 15 years of age.Cancer 1986; 58: 598–602.
Wieland DM, Wu J, Brown LE, Mangner TJ, Swanson DP, Beierwaltes WH. Radiolabeled adrenergic neuron-blocking agents: adrenomedullary imaging with131I metaiodobenzyl-guanidine.J Nucl Med 1980; 21: 349–353.
Hattner RS, Huberty JP, Engelstad BL, Gooding CA, Ablin AR. Localization ofm-iodo (I-131) benzylguanidine in neuroblastoma.AJR 1984; 143: 373–374.
Lumbroso JD, Guermazi F. Hartmann O, et al. Meta-iodobenzylguanidine (mIBG) scans in neuroblastoma: sensitivity and specificity, a review of 115 scans.Prog Clin Biol Res 1988; 271: 689–705.
Parisi MT, Greene MK, Dykes TM, Moraldo TV, Sandler ED, Hattner RS. Efficacy of metaiodobenzylguanidine as a scintigraphic agent for the detection of neuroblastoma.Invest Radiol 1992; 10: 768–772.
Gelfand MJ. Meta-iodobenzylguanidine in children.Semin Nucl Med 1993; 23: 231–242.
Hoefnagel CA, DeKraker J, Valdes Olmos RA, Voute P.123I-MIBG as a first-line treatment in high-risk neuroblastoma patients.Nucl Med Commun 1994; 15: 712.
Garty I, Friedman A, Sandler MP, Kedar A. Neuroblastoma: imaging evaluation by sequential Tc-99m MDP, I-131 MIBG, and Ga-67 citrate studies.Clin Nucl Med 1988; 14: 515–522.
Waters BW, Sievert H, Linden A. Immunoscintigraphic imaging of mIBG. Negative metastases in neuroblastoma.Am J Pediatr Hemat Oncol 1990; 12: 61–62.
Gordon I, Peters AM, Gutman A, Morony S, Dicks-Mireaux C, Pritchard J. Tc-99m bone scans are more sensitive than I-123 MIBG scans for bone imaging in neuroblastoma.J Nucl Med 1990; 31: 129–134.
Yeh SD, Larson SM, Bruch L, et al. Radioimmunodetection of neuroblastoma with iodine-131-3F8: correlation with biopsy, iodine- 131-metaiodobenzylguanidine and standard diagnostic modalities.J Nucl Med 1991; 32: 769–776.
Shulkin BL, Shapiro B, Hutchinson RJ. Iodine- 131-metaiodo-benzylguanidine and bone scintigraphy for the detection of neuroblastoma.J Nucl Med 1992; 33: 1735–1740.
Corbett R, Olliff J, Fairley N, et al. A prospective comparison between magnetic resonance imaging, metaiodobenzylguanidine scintigraphy and marrow histology/cytology in neuroblastoma.Eur J Cancer 1991; 27: 1560–1564.
Najean BB, Siles S, Pannuel M, et al. Value of MRI and MIBG-1123 scintigraphy in the diagnosis of spinal bone marrow involvement in neuroblastoma in children.Pediatr Radiol 1992; 22: 443–446.
Parisi MT, Matthay KK, Huberty JP, Hattner RS. Neuroblastoma: dose-related sensitivity of MIBG scanning in detection.Radiology 1992; 184: 463–467.
Preisman R, Halpern S. Detection of metastatic thyroid carcinoma after the administration of a therapeutic dose of 131-iodine.Eur J Nucl Med 1978; 3: 69–70.
Pacini F, Lippi F, Formica N, et al. Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels.J Nucl Med 1987;28: 1888–1891.
Schlumberger M, Arcangioli O, Piekarski JD, Tubiana M, Parmentier C. Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays.J Nucl Med 1988; 29: 1790–1794.
Bonnin F, Lumbroso J, Tenenbaum F, Hartmann O, Parmentier C. Refining interpretation of mIBG scans in children.J Nucl Med 1994; 35: 803–810.
Lumbroso J, Aubert B, Ricard M, et al. Dosimetry in metabolic radiotherapy using I-131 metaiodobenzylguanidine (mIBG) for neuroblastoma and pheochromocytoma.J Nucl Med 1986; 27: 1008 (A).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Giammarile, F., Lumbroso, J., Ricard, M. et al. Radioiodinated metaiodobenzylguanidine in neuroblastoma: influence of high dose on tumour site detection. Eur J Nucl Med 22, 1180–1183 (1995). https://doi.org/10.1007/BF00800601
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00800601